| Anthony Emmanuel Mega, MD | |
|
164 Summit Avenue, Fain 3, Providence, RI 02906-2853 | |
| (401) 793-2920 | |
| (401) 793-2859 |
| Full Name | Anthony Emmanuel Mega |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 36 Years |
| Location | 164 Summit Avenue, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457309858 | NPI | - | NPPES |
| 7004818 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD08901 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Home & Hospice Care Of Rhode Island | Providence, RI | Hospice |
| Rhode Island Hospital | Providence, RI | Hospital |
| The Miriam Hospital | Providence, RI | Hospital |
| Newport Hospital | Newport, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rhode Island Hospital | 8921900044 | 303 |
News Archive
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.
New ethics committee regulations impede and delay clinical research, sometimes to the extent that conclusions are flawed and patients damaged, according to several articles in this week's BMJ.
› Verified 2 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396849782 PECOS PAC ID: 8921900044 Enrollment ID: O20050211000311 |
News Archive
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.
New ethics committee regulations impede and delay clinical research, sometimes to the extent that conclusions are flawed and patients damaged, according to several articles in this week's BMJ.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Emmanuel Mega, MD 164 Summit Avenue, Providence, RI 02906-2853 Ph: (401) 793-4001 | Anthony Emmanuel Mega, MD 164 Summit Avenue, Fain 3, Providence, RI 02906-2853 Ph: (401) 793-2920 |
News Archive
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.
New ethics committee regulations impede and delay clinical research, sometimes to the extent that conclusions are flawed and patients damaged, according to several articles in this week's BMJ.
› Verified 2 days ago
Christopher Donald Palmer, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 Fax: 401-453-7597 | |
Martha Catherine Trimbur, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 245 Chapman St Ste 300, Providence, RI 02905 Phone: 401-444-4741 Fax: 401-444-4445 | |
Karl Herman, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Fain Bldg., Providence, RI 02906 Phone: 401-793-4489 Fax: 401-793-4047 | |
Muhammad Baig, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Fain Bldg, Providence, RI 02906 Phone: 401-793-4489 Fax: 401-793-4047 | |
Dr. Peter Sidhom, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 603-560-2276 | |
Dr. Kanhai Farrakhan, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-457-3336 Fax: 401-525-2349 | |
Gary M Katzman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 208 Collyer Street, Suite 100, Providence, RI 02904 Phone: 401-793-7191 Fax: 401-793-7200 |